ArticlemSphere2021
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa.
Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- Comparative efficacy of ceftolozane-tazobactam versus ceftazidime-avibactam forAnnals of medicine and surgery (2012) · 2026Article
- AMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction.Nature communications · 2026Article
- Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.The Journal of infectious diseases · 2026Article
- Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli.Microbiology spectrum · 2025Article
- Companion Animals as Reservoirs of Multidrug Resistance-A Rare Case of an XDR, NDM-1-ProducingVeterinary sciences · 2025Article
- Metabolic state-driven nutrient-based approach to combat bacterial antibiotic resistance.npj antimicrobials and resistance · 2025Review
- The relationship between virulence and drug resistance genes inFrontiers in cellular and infection microbiology · 2025Article
- Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility inFrontiers in microbiology · 2025Article
- Three prolonged outbreaks of metallo-β-lactamase-producingMicrobiology spectrum · 2024Article
- Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-ResistantMicrobiology spectrum · 2023Article
- Evolving landscape of carbapenem-resistantJAC-antimicrobial resistance · 2023Article
- Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.Microbiology spectrum · 2023Article
- Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.The Journal of antimicrobial chemotherapy · 2022Article
- Reversion of Ceftazidime Resistance inMicroorganisms · 2022Article
- Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.Microbiology spectrum · 2022Article
- Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa.Microbiology spectrum · 2022Article
- Antimicrobial Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
This study established the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.